Have a question?
Please get in touch with our team in case of any queries
THE GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE TO REACH USD 4 BILLION BY 2026, GROWING AT A CAGR OF 13% DURING THE FORECAST PERIOD
Vaccine Contract Manufacturing Market Size, Share, Trends Analysis Report by Scale of Operation (Commercial, Clinical, and Preclinical); Vaccine Type (Sub-unit, Live Attenuated, Inactivated, RNA, and Others); Services (Fill/Finish, Analytical & QC Studies, Cell/Virus Banking, and Others); and Geography (North America, Europe, APAC, Latin America, and Middle East & Africa); Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021–2026
This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize
GLOBAL VACCINE CONTRACT MANUFACTURING MARKET REPORT SCOPE
| REPORT ATTRIBUTE | DETAILS |
|---|---|
| MARKET SIZE (REVENUE) | 4 BILLION (2026) |
| CAGR | 13% (2021–2026) |
| Base Year | 2020 |
| Forecast Year | 2021–2026 |
| Market Segments | Scales of Operation (Commercial, Clinical, and Preclinical); Vaccine Type (Sub-unit, Live Attenuated, Inactivated, RNA, and Others); Services (Fill/Finish, Analytical & QC Studies, Cell/Virus Banking, and Others) |
| Geographic Analysis | North America, Europe, APAC, Latin America, and Middle East & Africa |
| Countries Covered | US, Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, Australia, India, Brazil, Mexico, Argentina, Saudi Arabia, Turkey, South Africa |
VACCINE CONTRACT MANUFACTURING MARKET INSIGHTS
The global vaccine contract manufacturing market size to reach USD 4 billion by 2026, growing at a CAGR of 13% during the period 2021-2026. The global market has experienced radical transformations after the outbreak of the COVID-19 pandemic, which has been a massive health catastrophe. The commercial segment accounted for 64.53% of the global vaccine contract manufacturing market share in 2020. This is mainly due to the requirement of large-scale production of vaccines, especially during epidemics/pandemics.
Companies such as Johnson & Johnson, AstraZeneca-University of Oxford, Pfizer-BioNTech, Moderna, Novavax, Inovio, and Vaxart have formed international alliances to fast-track development and clinical trials and simultaneously set up vaccine manufacturing and distribution networks worldwide.
IMPACT OF COVID-19
A new era of vaccine and biological drug development has prevailed since the advent of the COVID-19 virus. The global pandemic has fueled vaccine innovations with the rapid acceleration of RNA-based COVID vaccines. Contract manufacturing companies are working to increase the availability of COVID-19 vaccines across the globe. In the development of the COVID-19 vaccine, pharma companies, CMOs, and suppliers are racing against time to introduce a larger production and supply chain plan so the vaccines can reach people speedily and securely. Vaccine sponsors as large as AstraZeneca and Johnson & Johnson are using CMOs for their pipeline vaccines. AstraZeneca’s AZD-1222, the COVID-19 vaccine candidate, has made manufacturing agreements with 12 service providers, including key players such as Emergent BioSolutions, Novasep, Catalent, and Merck, for its excess capacity manufacturing.
In Europe, the mass production of the COVID-19 vaccine is increasing at a faster rate. For instance, Novavax is utilizing its recently acquired manufacturing facility located in Bohumil in the Czech Republic to produce its own vaccine. Sanofi is investing more than USD 610 million in an advanced production site located in Neuville-sur-Saône as well as in a new vaccine research center in Marcy-l’Etoile. Such strategies will help the mass production of vaccines throughout the world.
GEOGRAPHICAL MARKET SHARE
North America contributed the highest revenue with a market share of 35.40% in the global vaccine contract manufacturing market share in 2020. North America has the most widespread contract manufacturing organizations (CMOs), with nearly 40 CMOs present at several US locations. The US accounted for over 90% of the North American vaccine contract manufacturing market share. The market observes the highest growth in this region due to the presence of major biopharmaceutical companies for clinical studies, increasing populations, the spread of bacterial and viral infections, growing hospitalization, and the growing demand for vaccinations.
Europe accounted for the second-highest share of 26% in the vaccine contract manufacturing market in 2020. The increasing elderly population, prevalence of bacterial and viral infections, increasing demand for new vaccinations, and expanding biopharma and biotech industry are major factors contributing to the growth of biopharmaceutical contract manufacturing in the Europe region.
APAC is expected to emerge as the fastest-growing market due to the prevalence of infectious diseases and high adoption of vaccinations to prevent these diseases. APAC is expected to witness the highest absolute growth of 118.91% and the highest CAGR of 13.95% during the forecast period.
SNIPPETS
- The spread of infectious diseases across regions and the subsequent implementation of vaccination programs have raised the clinical demand for vaccines, thereby driving the market growth.
- The vaccine contract manufacturing market in India expect to grow at a CAGR of over 15% during 2020–2026.
- The clinical vaccine contract manufacturing market is likely to observe an absolute growth of over 113% during the forecast period.
- The sub-unit market is likely to account for the highest incremental growth of over USD 633 million during the forecast period.
- APAC is likely to observe the highest CAGR because of the high prevalence of infectious diseases, high demand for vaccine programs, and the presence of several contract manufacturers.
GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SEGMENTATION
This research report includes a detailed segmentation by
- Scale of Operation
- Vaccine Type
- Services
- Geography
The global commercial vaccine contract manufacturing market accounted for over 64% in 2020.
There has been a high demand for contract manufacturing services due to the growth in infectious diseases and the onset of endemics and pandemics worldwide. North America expects to contribute maximum revenue to the commercial vaccine market due to the increased focus to prevent deaths caused by vaccine-preventable diseases. The emergence of the RNA platform has accelerated the vaccine development process.
The clinical vaccine contract manufacturing market is expected to witness an incremental growth of over USD 492 million during the forecast period.
Several serums are in the pipeline for wide-ranging contagious diseases and COVID-19, which are likely to boost the market growth. The preclinical segment accounted for a share of 13% of the global vaccine contract manufacturing market in 2020. Growing populations, healthcare awareness, demand for newer vaccination products, increasing global vaccination coverage are also some of the factors for the increased need for immunizations globally.
Sub-unit vaccines accounted for a major share of approx. 34% in 2020, and they are likely to witness the highest incremental growth of over USD 633 million during the forecast period.
Growing infectious diseases leading to endemic/pandemics, majorly due to decreasing immunization coverage in many regions, have made national and international bodies implement vaccination programs strictly, allowing more people to get vaccinated. This is likely to increase the demand for vaccine production and benefit CMOs’ expertise in the manufacturing services. Contract manufacturing service agreements are high for recombinant vector COVID-19 vaccines.
The global live-attenuated vaccines contract manufacturing market expects to cross over USD 1 billion by 2026.
Live attenuated serums are among the most widely used vaccination technologies. They have complex manufacturing requirements, which increase pharma and biotech R&D budgets. Therefore, companies try to meet vaccine demands via a low-cost and highly effective manufacturing process, thereby facilitating contract manufacturing services.
The fill/finish services market expects to grow at a CAGR of approx. 13% during 2020-2026.
Fill/finish services are subject to extreme scrutiny by regulatory agencies and tend to be costly in the manufacturing process. Hence, vaccine manufacturers outsource these services to CMOs, which help them meet unexpected demands, source policies or better matching scales. Moreover, biopharmaceutical companies outsource fill-and-finish needs to gain access to specialized technology. CMOs are extremely helpful in meeting balanced production volumes and commercial validation of manufactured products. Hence, the growth in biopharmaceuticals is likely to fuel the demand for fill-and-finish contract services.
COMPETITOR MARKET SHARE
Ajinomoto BioPharma, Albany Molecular Research Institute, Catalent, Cytovance Biologics, Emergent Biosolutions, Fujifilm Diosynth Biotechnologies, and GlaxoSmithKline are a few vendors accounting for the global vaccine contract manufacturing market share. Established players are entering into strategic alliances and co-marketing agreements to elevate the market competitiveness and penetration. They also make long-term relationships with distributors and suppliers for scale-up production and expand geographical presence in the market. North America offers a high quantity of contract manufacturing service offerings. Europe and APAC have a few prominent players and several small and mid-sized vendors. Emerging economies, including China, India, Brazil, and Mexico, are likely to offer significant growth opportunities for vendors.
The global vaccine contract manufacturing market research report includes in-depth coverage of the market dynamics with revenue, supply chain, and forecast insights for the following segments:
Scale of Operation
- Commercial
- Clinical
- Pre-clinical
Vaccine Type
- Sub-unit
- Live Attenuated
- Inactivated
- RNA
- Others
Services
- Fill/Finish
- Analytical & QC Studies
- Cell/Virus Banking
- Others
Geography
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- APAC
- China
- India
- Japan
- South Korea
- Australia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Saudi Arabia
- Turkey
- South Africa
Frequently Asked Questions
How big is the vaccine contract manufacturing market?
Which segment is likely to generate the largest revenue during the forecast period?
Which region has the largest number of vaccine manufacturers?
Who are the top vaccine manufacturers?
How has COVID-19 pandemic affected contract manufacturing companies?
What limitations are associated with the supply of COVID-19 vaccines for CMOs?
The global vaccine contract manufacturing market by revenue is expected to grow at a CAGR of approx. 13% during the period 2020–2026.
The following factors are likely to contribute to the growth of the vaccine contract manufacturing market during the forecast period:
- Global COVID-19 Vaccination Programs
- Manufacturers’ focus on Scale-up Vaccine Production
- Growing Agreements between Vaccine Developers and Contract Manufacturers
- Vaccine pipeline boosting demand for Contract Manufacturing
Base Year: 2020
Forecast Year: 2021–2026
The study considers the global vaccine contract manufacturing market’s present scenario and its market dynamics for the period 2020−2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.
Prominent Vendors
- Ajinomoto Bio-Pharma
- Business Overview
- Product Offerings
- Key Strengths
- Key Strategies
- Key Opportunities
- Albany Molecular Research (AMRI)
- Catalent
- Cytovance Biologics
- Emergent BioSolutions
- FUJIFILM
- GlaxoSmithKline
- IDT Biologika
- Lonza
- Merck KGaA
- Pfizer
- Recipharm
- Serum Institute of India
- Siegfried Holding
Other Prominent Vendors
- Cobra Biologics
- Business Overview
- Product Offerings
- Baxter BioPharma Solutions
- Goodwin Biotechnology
- KBI Biopharma
- Sanofi
- BioMARC
- Bavarian Nordic
- Charles River Laboratories
- Boehringer Ingelheim
- Samsung Biologics
- Meridian Life Science
- Wacker Biotech B.V
- Jubilant HollisterStier
- AbbVie
- Novasep
- Kemwell Biopharma
- Northway Biotech
- Midas Pharma
- Alcami
- Cambrex
- Asymchem
- Pharmaceutics International Inc. (Pii)
- Sharp
- Singota Solutions
- Thermo Fisher Scientific
- Kaneka Eurogentec
- Richter-Helm BioLogics
- Ology Bioservices
- Corden Pharma
- Cerbios Pharma
- BSP Pharmaceuticals
- JOINN Biologics
- Eurofins Scientific
- ProBioGen
- Esco Aster
- Genovior Biotech
- AGC Biologics
- EirGenix
- Amaran Biotech
- Eden Biologics
- Abzena
- Aldevron
- Cell Culture Company
- Taron Solutions
- MabPlex
- Axcellerate Pharma
- WuXi Biologics
- Therapure Biopharma
Scale of Operation
- Commercial
- Clinical
- Pre-clinical
Vaccine Type
- Sub-unit Vaccines
- Live Attenuated Vaccines
- Inactivated Vaccines
- RNA Vaccines
- Others
Services
- Fill/Finish
- Analytical & QC Studies
- Cell/Virus Banking
- Others
Geography
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- APAC
- China
- India
- Japan
- South Korea
- Australia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Saudi Arabia
- Turkey
- South Africa
List of Exhibits
Exhibit 1 Segmentation of Global Vaccine Contract Manufacturing Market
Exhibit 2 Market Size Calculation Approach 2020
Exhibit 3 Factors Considered Before a Partnership with Contract Manufacturers
Exhibit 4 Opportunities for Contract Manufacturers
Exhibit 5 Impact of Global Vaccination Programs for COVID-19
Exhibit 6 Impact of Manufacturers’ Focus on Scale-Up Vaccine Production
Exhibit 7 Impact of Growing Agreements Between Vaccine Developers and Contract Manufacturers
Exhibit 8 Vaccine Production Outsourcers from Buyer Groups
Exhibit 9 Impact of Vaccine Pipeline Boosting the Demand for Contract Manufacturing
Exhibit 10 Vaccines in the Pipeline for Various Infectious Diseases
Exhibit 11 DCVMN Pipeline: Number of Vaccine Projects in Development (2019)
Exhibit 12 Impact of Favorable Patient Demographics & Growing Vaccinations of Newborns and Children
Exhibit 13 Disease Incidence in the World 2020 (million)
Exhibit 14 Global Vaccination Coverage of 1-year-olds in 2019
Exhibit 15 Eradication of Major Diseases Through Vaccines in US
Exhibit 16 Impact of Effect of Epidemics & Pandemics on Vaccine Development
Exhibit 17 Number of Epidemic Events During 2011-2017
Exhibit 18 Impact of Cost-Effective and Time-Saving Services of Contract Manufacturers
Exhibit 19 Major Advantages of Engaging with CMOs
Exhibit 20 Impact of High Costs and Stockout Issues of Vaccines
Exhibit 21 Reported Stockouts of Vaccines During 2010-2018
Exhibit 22 Impact of Lack of Storage Infrastructure & Limitations Associated with Supply Chain
Exhibit 23 Major Barriers to Effective Vaccine Handling and Storage
Exhibit 24 Impact of Vaccination Concerns in Low- and Middle-Income Countries
Exhibit 25 Ten Most Frequently Reported Vaccination Concerns in LMICs
Exhibit 26 Global Vaccine Contract Manufacturing Market 2020–2026 ($ million)
Exhibit 27 Global Vaccine Contract Manufacturing Market by Scale of Operations
Exhibit 28 Global Vaccine Contract Manufacturing Market by Geography
Exhibit 29 Global Vaccine Contract Manufacturing Market by Vaccine type
Exhibit 30 Global Vaccine Contract Manufacturing Market by Service
Exhibit 31 Five Forces Analysis 2020
Exhibit 32 Incremental Growth by Scale of Operations 2020 & 2026
Exhibit 33 Global Vaccine Contract Manufacturing Market by Scale of Operations
Exhibit 34 Vaccine Pipeline for Various Infectious Diseases 2020
Exhibit 35 COVID-19 Vaccine Candidates in Various Clinical Stages of Development
Exhibit 36 Global Vaccine Contract Manufacturing Market by Scale of Operations: Incremental Growth
Exhibit 37 Global Vaccine Contract Manufacturing Market by Scale of Operations: Absolute Growth
Exhibit 38 Global Vaccine Contract Manufacturing Market by Commercial Segment: Incremental & Absolute Growth
Exhibit 39 Vaccines in the Pipeline for Various Diseases in 2020
Exhibit 40 Vaccines in the Pipeline by Disease Type in 2020
Exhibit 41 Global Vaccine Contract Manufacturing Market by Commercial Segment 2020–2026 ($ million)
Exhibit 42 Incremental Growth by Geography 2020 & 2026
Exhibit 43 Global Vaccine Contract Manufacturing Market by Clinical Segment: Incremental & Absolute Growth
Exhibit 44 Global Vaccine Contract Manufacturing Market by Clinical Segment 2020–2026 ($ million)
Exhibit 45 Incremental Growth by Geography 2020 & 2026
Exhibit 46 Global Vaccine Contract Manufacturing Market by Preclinical Segment: Incremental & Absolute Growth
Exhibit 47 Global Vaccine Contract Manufacturing Market by Preclinical Segment 2020–2026 ($ million)
Exhibit 48 Incremental Growth by Geography 2020 & 2026
Exhibit 49 Incremental Growth by Vaccine Type 2020 & 2026
Exhibit 50 Global Vaccine Contract Manufacturing Market by Vaccine Type
Exhibit 51 Different Types of COVID-19 Vaccines Under Research by 2020
Exhibit 52 Global Vaccine Contract Manufacturing Market by Vaccine Type: Incremental Growth
Exhibit 53 Global Vaccine Contract Manufacturing Market by Vaccine Type: Absolute Growth
Exhibit 54 Global Vaccine Contract Manufacturing Market by Sub-Unit Vaccines: Incremental & Absolute Growth
Exhibit 55 Global Vaccine Contract Manufacturing Market by Sub-Unit Vaccines 2020–2026 ($ million)
Exhibit 56 Incremental Growth by Geography 2020 & 2026
Exhibit 57 Global Vaccine Contract Manufacturing Market by Live-Attenuated Vaccines: Incremental & Absolute Growth
Exhibit 58 Global Vaccine Contract Manufacturing Market by Live-Attenuated Vaccines 2020–2026 ($ million)
Exhibit 59 Incremental Growth by Geography 2020 & 2026
Exhibit 60 Global Vaccine Contract Manufacturing Market by Inactivated Vaccines: Incremental & Absolute Growth
Exhibit 61 Global Vaccine Contract Manufacturing Market by Inactivated Vaccines 2020–2026 ($ million)
Exhibit 62 Incremental Growth by Geography 2020 & 2026
Exhibit 63 Global Vaccine Contract Manufacturing Market by RNA Vaccines: Incremental & Absolute Growth
Exhibit 64 Global Vaccine Contract Manufacturing Market by RNA Vaccines 2020–2026 ($ million)
Exhibit 65 Incremental Growth by Geography 2020 & 2026
Exhibit 66 Global Vaccine Contract Manufacturing Market by Others: Incremental & Absolute Growth
Exhibit 67 Global Vaccine Contract Manufacturing Market by Others 2020–2026 ($ million)
Exhibit 68 Incremental Growth by Geography 2020 & 2026
Exhibit 69 Incremental Growth by Service 2020 & 2026
Exhibit 70 Global Vaccine Contract Manufacturing Market by Service
Exhibit 71 Major Biopharmaceutical Contract Manufacturing Services
Exhibit 72 Global Vaccine Contract Manufacturing Market by Service: Incremental Growth
Exhibit 73 Global Vaccine Contract Manufacturing Market by Service: Absolute Growth
Exhibit 74 Global Vaccine Contract Manufacturing Market by Fill/Finish: Incremental & Absolute Growth
Exhibit 75 Outsourcing Fill-And-Finish Services to CMOs
Exhibit 76 Global Vaccine Contract Manufacturing Market by Fill/Finish Services 2020–2026 ($ million)
Exhibit 77 Incremental Growth by Geography 2020 & 2026
Exhibit 78 Analytical and QC Services Outsourced by Biopharma Manufacturers
Exhibit 79 Global Vaccine Contract Manufacturing Market by Analytical & QC Studies: Incremental & Absolute Growth
Exhibit 80 Global Vaccine Contract Manufacturing Market by Analytical & QC Studies 2020–2026 ($ million)
Exhibit 81 Incremental Growth by Geography 2020 & 2026
Exhibit 82 Protein Expression Systems Offered by Top CMOs
Exhibit 83 Global Vaccine Contract Manufacturing Market by Cell/Virus Banking: Incremental & Absolute Growth
Exhibit 84 Global Vaccine Contract Manufacturing Market by Cell/Virus Banking 2020–2026 ($ million)
Exhibit 85 Incremental Growth by Geography 2020 & 2026
Exhibit 86 Global Vaccine Contract Manufacturing Market by Others: Incremental & Absolute Growth
Exhibit 87 Biopharma Companies Outsourcing Their Regulatory Requirements
Exhibit 88 Global Vaccine Contract Manufacturing Market by Others 2020–2026 ($ million)
Exhibit 89 Incremental Growth by Geography 2020 & 2026
Exhibit 90 Incremental Growth by Geography 2020 & 2026
Exhibit 91 Global Vaccine Contract Manufacturing Market by Geography
Exhibit 92 Global Vaccine Contract Manufacturing Market by Geography: Key Countries ($ million)
Exhibit 93 Global Vaccine Contract Manufacturing Market by Geography: Incremental Growth
Exhibit 94 Global Vaccine Contract Manufacturing Market by Geography: Absolute Growth
Exhibit 95 Market Share of Major Countries in North America
Exhibit 96 Deaths Caused by Vaccine-Preventable Diseases in North America (2013-2017)
Exhibit 97 Vaccine Contract Manufacturing Market in North America: Key Countries 2020
Exhibit 98 Vaccine Contract Manufacturing Market in North America: Incremental & Absolute Growth
Exhibit 99 Vaccine Contract Manufacturing Market in North America 2020–2026 ($ million)
Exhibit 100 Incremental Growth by Scale of Operations 2020 & 2026
Exhibit 101 Incremental Growth by Vaccine Type 2020 & 2026
Exhibit 102 Incremental Growth by Service 2020 & 2026
Exhibit 103 Incremental Growth in North America 2020 & 2026
Exhibit 104 Major Infectious Diseases Causing Deaths in the US
Exhibit 105 Vaccine Contract Manufacturing Market in the US 2020–2026 ($ million)
Exhibit 106 Number of Deaths Caused by Major Infectious Diseases in Canada
Exhibit 107 Vaccination Coverage in Children Aged 1 Year in Canada
Exhibit 108 Vaccine Contract Manufacturing Market in Canada 2020–2026 ($ million)
Exhibit 109 Market Share of Major Countries in Europe
Exhibit 110 Burden of Vaccine-Preventable Diseases in Europe 2009–2013
Exhibit 111 Vaccine Contract Manufacturing Market in Europe: Key Countries 2020
Exhibit 112 Vaccine Contract Manufacturing Market in Europe: Incremental & Absolute Growth
Exhibit 113 Vaccine Contract Manufacturing Market in Europe 2020–2026 ($ million)
Exhibit 114 Incremental Growth by Scale of Operations 2020 & 2026
Exhibit 115 Incremental Growth by Vaccine Type 2020 & 2026
Exhibit 116 Incremental Growth by Service 2020 & 2026
Exhibit 117 Incremental Growth in Europe 2020 & 2026
Exhibit 118 Deaths Caused by Vaccine-Preventable Diseases in Germany
Exhibit 119 Vaccine Contract Manufacturing Market in Germany 2020–2026 ($ million)
Exhibit 120 Vaccine-Preventable Diseases Causing Deaths in the UK
Exhibit 121 Vaccine Contract Manufacturing Market in the UK 2020–2026 ($ million)
Exhibit 122 Major Infectious Diseases Causing Deaths in France
Exhibit 123 Target Population Immunized for Vaccine-Preventable Diseases
Exhibit 124 Vaccine Contract Manufacturing Market in France 2020–2026 ($ million)
Exhibit 125 Deaths due to Vaccine-Preventable Diseases in Italy
Exhibit 126 Vaccine Contract Manufacturing Market in Italy 2020–2026 ($ million)
Exhibit 127 Major Vaccine-Preventable Diseases Causing Deaths in Spain
Exhibit 128 Vaccine Contract Manufacturing Market in Spain 2020–2026 ($ million)
Exhibit 129 Market Share of Major Countries in APAC
Exhibit 130 Vaccine Contract Manufacturing Market in APAC: Key Countries 2020
Exhibit 131 Vaccine Contract Manufacturing Market in APAC: Incremental & Absolute Growth
Exhibit 132 Vaccine Contract Manufacturing Market in APAC 2020–2026 ($ million)
Exhibit 133 Incremental Growth by Scale of Operations 2020 & 2026
Exhibit 134 Incremental Growth by Vaccine Type 2020 & 2026
Exhibit 135 Incremental Growth by Service 2020 & 2026
Exhibit 136 Incremental Growth in APAC 2020 & 2026
Exhibit 137 Major Vaccine-Preventable Diseases Causing Deaths in China
Exhibit 138 Vaccine Contract Manufacturing Market in China 2020–2026 ($ million)
Exhibit 139 Major Infectious Diseases Causing Mortality in India
Exhibit 140 Vaccine Contract Manufacturing Market in India 2020–2026 ($ million)
Exhibit 141 Deaths Caused due to Various Infectious Diseases in Japan
Exhibit 142 Vaccine Contract Manufacturing Market in Japan 2020–2026 ($ million)
Exhibit 143 Deaths due to Vaccine-Preventable Diseases in South Korea
Exhibit 144 Vaccine Contract Manufacturing Market in South Korea 2020–2026 ($ million)
Exhibit 145 Deaths Caused by Infectious Diseases in Australia
Exhibit 146 Vaccine Contract Manufacturing Market in Australia 2020–2026 ($ million)
Exhibit 147 Market share of major countries in Latin America
Exhibit 148 Deaths Caused by Vaccine-Preventable Diseases
Exhibit 149 Vaccine Contract Manufacturing Market in Latin America: Key Countries 2020
Exhibit 150 Vaccine Contract Manufacturing Market in Latin America: Incremental & Absolute Growth
Exhibit 151 Vaccine Contract Manufacturing Market in Latin America 2020–2026 ($ million)
Exhibit 152 Incremental Growth by Scale of Operations 2020 & 2026
Exhibit 153 Incremental Growth by Vaccine Type 2020 & 2026
Exhibit 154 Incremental Growth by Service 2020 & 2026
Exhibit 155 Incremental Growth in Latin America 2020 & 2026
Exhibit 156 Major Deaths Caused due to Vaccine-Preventable Diseases
Exhibit 157 National Immunization Coverage for Brazil (%)
Exhibit 158 Vaccine Contract Manufacturing Market in Brazil 2020–2026 ($ million)
Exhibit 159 Deaths Caused by Vaccine-Preventable Diseases
Exhibit 160 Vaccine Contract Manufacturing Market in Mexico 2020–2026 ($ million)
Exhibit 161 Deaths Caused due to Vaccine-Preventable Diseases
Exhibit 162 Vaccine Contract Manufacturing Market in Argentina 2020–2026 ($ million)
Exhibit 163 Market Share of Major Countries in the Middle East & Africa
Exhibit 164 Vaccine-Preventable Diseases Causing Mortality in the Middle East & Africa
Exhibit 165 Vaccine Contract Manufacturing Market in the Middle East & Africa: Key Countries 2020
Exhibit 166 Vaccine Contract Manufacturing Market in the Middle East & Africa: Incremental & Absolute Growth
Exhibit 167 Vaccine Contract Manufacturing Market in the Middle East & Africa 2020–2026 ($ million)
Exhibit 168 Incremental Growth by Scale of Operations 2020 & 2026
Exhibit 169 Incremental Growth by Vaccine Type 2020 & 2026
Exhibit 170 Incremental Growth by Service 2020 & 2026
Exhibit 171 Incremental Growth in the Middle East & Africa 2020 & 2026
Exhibit 172 Deaths Caused by Vaccine-Preventable Diseases
Exhibit 173 Target Population Immunized for Vaccine-Preventable Diseases
Exhibit 174 Vaccine Contract Manufacturing Market in South Africa 2020–2026 ($ million)
Exhibit 175 Deaths Caused by Vaccine-Preventable Diseases
Exhibit 176 Vaccine Contract Manufacturing Market in Saudi Arabia 2020–2026 ($ million)
Exhibit 177 Deaths due to Vaccine-Preventable Diseases in Turkey
Exhibit 178 Vaccine Contract Manufacturing Market in Turkey 2020–2026 ($ million)
Exhibit 179 Ajinomoto: Revenue 2017-2019 ($ billion)
Exhibit 180 Ajinomoto: Revenue by Segments 2018-2019 ($ billion)
Exhibit 181 Ajinomoto: Revenue Share by Geographical Region 2019 ($ billion)
Exhibit 182 Catalent: Revenue 2018-2020 ($ million)
Exhibit 183 Catalent: Revenue Share by Geographical Region 2020 & 2019 ($ million)
Exhibit 184 Emergent BioSolutions: Revenue 2018-2020 ($ million)
Exhibit 185 Emergent BioSolutions: Revenue by Segments 2019-2020 ($ million)
Exhibit 186 FUJIFILM: Revenue 2017-2019 ($ billion)
Exhibit 187 FUJIFILM: Revenue by Segments 2018-2019 ($ billion)
Exhibit 188 GSK: Revenue 2017-2020 ($ billion)
Exhibit 189 GSK: Revenue by Segments 2018-2019 ($ billion)
Exhibit 190 GSK: R&D Expenditure During 2018-2019 ($ million)
Exhibit 191 GSK: Revenue Share by Geographical Region During 2018-2019 ($ million)
Exhibit 192 Lonza: Revenue 2018-2019 ($ million)
Exhibit 193 Lonza: Revenue by Segments 2018-2019 ($ million)
Exhibit 194 Lonza: Revenue Share by Geographical Region 2019 ($ million)
Exhibit 195 Merck KGaA: Revenue Share During 2017-2020 ($ billion)
Exhibit 196 Pfizer: Revenue Share 2017-2019 ($ million)
Exhibit 197 Pfizer: Revenue by Segments 2018-2019 ($ million)
Exhibit 198 Pfizer: R&D Expenditure 2017-2019 ($ million)
Exhibit 199 Pfizer: Revenue Share by Geographical Region During 2018-2019 ($ million)
Exhibit 200 Recipharm: Revenue share 2017-2019 ($ million)
Exhibit 201 Recipharm: Revenue Share by Segments 2018-2019 ($ million)
Exhibit 202 Recipharm: Revenue Share by Geography 2018-2019 ($ million)
Exhibit 203 Siegfried: Revenue 2018-2020 ($ million)
List of Tables
Table 1 Key Caveats
Table 2 Currency Conversion 2013−2020
Table 3 WHO recommendations for priority use of COVID-19 vaccine during limited supply
Table 4 Current Vaccine Pipeline for Infectious Diseases
Table 5 Vaccines for Various Infectious and Cancer Diseases in Clinical Trials
Table 6 New Vaccine Candidates for Tuberculosis in Preclinical Phase in 2020
Table 7 Types of vaccines available for various infectious diseases
Table 8 Vaccine Contract Manufacturing Market in North America by Scale of Operations 2020−2026 ($ million)
Table 9 Vaccine Contract Manufacturing Market in North America by Scale of Operations 2020−2026 (%)
Table 10 Vaccine Contract Manufacturing Market in North America by Vaccine type 2020−2026 ($ million)
Table 11 Vaccine Contract Manufacturing Market in North America by Vaccine Type 2020−2026 (%)
Table 12 Vaccine Contract Manufacturing Market in North America by Service 2020−2026 ($ million)
Table 13 Vaccine Contract Manufacturing Market in North America by Service 2020−2026 (%)
Table 14 Vaccine Contract Manufacturing Market in Europe by Scale of Operations 2020−2026 ($ million)
Table 15 Vaccine Contract Manufacturing Market in Europe by Scale of Operations 2020−2026 (%)
Table 16 Vaccine Contract Manufacturing Market in Europe by Vaccine type 2020−2026 ($ million)
Table 17 Vaccine Contract Manufacturing Market in Europe by Vaccine type 2020−2026 (%)
Table 18 Vaccine Contract Manufacturing Market in Europe by Service 2020−2026 ($ million)
Table 19 Vaccine Contract Manufacturing Market in Europe by Service 2020−2026 (%)
Table 20 Vaccine Contract Manufacturing Market in APAC by Scale of Operations 2020−2026 ($ million)
Table 21 Vaccine Contract Manufacturing Market in APAC by Scale of Operations 2020−2026 (%)
Table 22 Vaccine Contract Manufacturing Market in APAC by Vaccine Type 2020−2026 ($ million)
Table 23 Vaccine Contract Manufacturing Market in APAC by Vaccine Type 2020−2026 (%)
Table 24 Vaccine Contract Manufacturing Market in APAC by Service 2020−2026 ($ million)
Table 25 Vaccine Contract Manufacturing Market in APAC by Service 2020−2026 (%)
Table 26 Vaccine Contract Manufacturing Market in Latin America by Scale of Operations 2020−2026 ($ million)
Table 27 Vaccine Contract Manufacturing Market in Latin America by Scale of Operations 2020−2026 (%)
Table 28 Vaccine Contract Manufacturing Market in Latin America by Vaccine Type 2020−2026 ($ million)
Table 29 Vaccine Contract Manufacturing Market in Latin America by Vaccine Type 2020−2026 (%)
Table 30 Vaccine Contract Manufacturing Market in Latin America by Service 2020−2026 ($ million)
Table 31 Vaccine Contract Manufacturing Market in Latin America by Service 2020−2026 (%)
Table 32 Vaccine Contract Manufacturing Market in the Middle East & Africa by Scale of Operations 2020−2026 ($ million)
Table 33 Vaccine Contract Manufacturing Market in the Middle East & Africa by Scale of Operations 2020−2026 (%)
Table 34 Vaccine Contract Manufacturing Market in the Middle East & Africa by Vaccine Type 2020−2026 ($ million)
Table 35 Vaccine Contract Manufacturing Market in the Middle East & Africa by Vaccine Type 2020−2026 (%)
Table 36 Vaccine Contract Manufacturing Market in the Middle East & Africa by Service 2020−2026 ($ million)
Table 37 Vaccine Contract Manufacturing Market in the Middle East & Africa by Service 2020−2026 (%)
Table 38 Ajinomoto: Major Service Offerings
Table 39 Albany Molecular Research: Major Service Offerings
Table 40 Catalent: Major Service Offerings
Table 41 Cytovance Biologics: Major Service Offerings
Table 42 Emergent BioSolutions: Major Service Offerings
Table 43 FUJIFILM: Major Service Offerings
Table 44 GSK: Major Service Offerings
Table 45 IDT Biologika: Major Service Offerings
Table 46 Lonza: Major Service Offerings
Table 47 Merck: Major Service Offerings
Table 48 Pfizer: Major Service Offerings
Table 49 Recipharm: Major Service Offerings
Table 50 Serum Institute of India: Major Service Offerings
Table 51 Siegfried: Major Service Offerings
Table 52 Cobra Biologics: Major Service Offerings
Table 53 Baxter Healthcare: Major Service Offerings
Table 54 Goodwin Biotechnology: Major Service Offerings
Table 55 KBI Biopharma: Major Service Offerings
Table 56 Sanofi: Major Service Offerings
Table 57 BioMARC: Major Service Offerings
Table 58 Bavarian Nordic: Major Service Offerings
Table 59 Charles River Laboratories: Major Service Offerings
Table 60 Boehringer Ingelheim: Major Service Offerings
Table 61 Samsung Biologics: Major Service Offerings
Table 62 Meridian Life Science: Major Service Offerings
Table 63 Wacker Biotech B.V: Major Service Offerings
Table 64 Jubilant HollisterStier: Major Service Offerings
Table 65 AbbVie: Major Service Offerings
Table 66 Novasep: Major Service Offerings
Table 67 Kemwell Biopharma: Major Service Offerings
Table 68 Northway Biotech: Major Service Offerings
Table 69 Midas Pharma: Major Service Offerings
Table 70 Alcami: Major Service Offerings
Table 71 Cambrex: Major Service Offerings
Table 72 Asymchem: Major Service Offerings
Table 73 Pharmaceutics International: Major Service Offerings
Table 74 Sharp: Major Service Offerings
Table 75 Singota Solutions: Major Service Offerings
Table 76 Thermo Fisher Scientific: Major Service Offerings
Table 77 Kaneka Eurogentec: Major Service Offerings
Table 78 Richter-Helm BioLogics: Major Service Offerings
Table 79 Ology Bioservices: Major Service Offerings
Table 80 Corden Pharma: Major Service Offerings
Table 81 Cerbios Pharma: Major Service Offerings
Table 82 BSP Pharmaceuticals: Major Service Offerings
Table 83 JOINN Biologics: Major Service Offerings
Table 84 Eurofins Scientific: Major Service Offerings
Table 85 ProBioGen: Major Service Offerings
Table 86 Esco Aster: Major Service Offerings
Table 87 Genovior Biotech: Major Service Offerings
Table 88 AGC Biologics: Major Service Offerings
Table 89 EirGenix: Major Service Offerings
Table 90 Amaran Biotech: Major Service Offerings
Table 91 Eden Biologics: Major Service Offerings
Table 92 Abzena: Major Service Offerings
Table 93 Aldevron: Major Service Offerings
Table 94 Cell Culture Company: Major Service Offerings
Table 95 Taron Solutions: Major Service Offerings
Table 96 MabPlex: Major Service Offerings
Table 97 Axcellerate Pharma: Major Service Offerings
Table 98 WuXi Biologics: Major Service Offerings
Table 99 Therapure Biopharma: Major Service Offerings
Table 100 Global Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 ($ million)
Table 101 Global Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 (%)
Table 102 North America Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 ($ million)
Table 103 North America Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 (%)
Table 104 Europe Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 ($ million)
Table 105 Europe Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 (%)
Table 106 APAC Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 ($ million)
Table 107 APAC Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 (%)
Table 108 Latin America Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 ($ million)
Table 109 Latin America Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 (%)
Table 110 Middle East & Africa Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 ($ million)
Table 111 Middle East & Africa Vaccine Contract Manufacturing Market by Scale of Operations 2020−2026 (%)
Table 112 Global Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 ($ million)
Table 113 Global Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 (%)
Table 114 North America Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 ($ million)
Table 115 North America Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 (%)
Table 116 Europe Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 ($ million)
Table 117 Europe Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 (%)
Table 118 APAC Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 ($ million)
Table 119 APAC Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 (%)
Table 120 Latin America Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 ($ million)
Table 121 Latin America Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 (%)
Table 122 Middle East & Africa Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 ($ million)
Table 123 Middle East & Africa Vaccine Contract Manufacturing Market by Vaccine type 2020−2026 (%)
Table 124 Global Vaccine Contract Manufacturing Market by Service 2020−2026 ($ million)
Table 125 Global Vaccine Contract Manufacturing Market by Service 2020−2026 (%)
Table 126 North America Vaccine Contract Manufacturing Market by Service 2020−2026 ($ million)
Table 127 North America Vaccine Contract Manufacturing Market by Service 2020−2026 (%)
Table 128 Europe Vaccine Contract Manufacturing Market by Service 2020−2026 ($ million)
Table 129 Europe Vaccine Contract Manufacturing Market by Service 2020−2026 (%)
Table 130 APAC Vaccine Contract Manufacturing Market by Service 2020−2026 ($ million)
Table 131 APAC Vaccine Contract Manufacturing Market by Service 2020−2026 (%)
Table 132 Latin America Vaccine Contract Manufacturing Market by Service 2020−2026 ($ million)
Table 133 Latin America Vaccine Contract Manufacturing Market by Service 2020−2026 (%)
Table 134 Middle East & Africa Vaccine Contract Manufacturing Market by Service 2020−2026 ($ million)
Table 135 Middle East & Africa Vaccine Contract Manufacturing Market by Service 2020−2026 (%)
Table 136 Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)
Table 137 Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)
Table 138 Commercial Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)
Table 139 Commercial Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)
Table 140 Clinical Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)
Table 141 Clinical Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)
Table 142 Preclinical Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)
Table 143 Preclinical Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)
Table 144 Sub-unit Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)
Table 145 Sub-unit Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)
Table 146 Live-attenuated Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)
Table 147 Live-attenuated Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)
Table 148 Inactivated Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)
Table 149 Inactivated Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)
Table 150 RNA Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)
Table 151 RNA Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)
Table 152 Others Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)
Table 153 Others Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)
Table 154 Fill/Finish Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)
Table 155 Fill/Finish Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)
Table 156 Analytical & QC Studies Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)
Table 157 Analytical & QC Studies Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)
Table 158 Cell/Virus banking Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)
Table 159 Cell/Virus banking Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)
Table 160 Others Vaccine Contract Manufacturing Market by Geography 2020−2026 ($ million)
Table 161 Others Vaccine Contract Manufacturing Market by Geography 2020−2026 (%)
1 Research Methodology
2 Research Objectives
3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope of The Study
4.4 Market Segments
4.4.1 Market Segmentation By Scale Of Operation:
4.4.2 Market Segmentation By Vaccine Type
4.4.3 Market Segmentation By Service
4.5.1 Market Segmentation By Geography
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at a Glance
7 Introduction
7.1 Overview
7.1.1 Advantages Associated with Contract Manufacturing Organization (CMO)
7.1.2 CMOs Gaining More Acceptance in Biopharmaceutical Industry
7.1.3 Characteristics of An Effective CMO
8 Market Opportunities & Trends
8.1 Global Vaccination Programs For COVID-19
8.2 Manufacturers’ Focus On Scale-Up Vaccine Production
8.3 Growing Agreements Between Vaccine Developers And Contract Manufacturers
8.4 Vaccine Pipeline Boosting The Demand For Contract Manufacturing
9 Market Growth Enablers
9.1 Favorable Patient Demographics & Growing Vaccinations Of Newborns And Children
9.2 Effect Of Epidemics & Pandemics On Vaccine Development
9.3 Cost-Effective And Time-Saving Services Of Contract Manufacturers
10 Market Restraints
10.1 High Costs and Stockout Issues Of Vaccines
10.2 Lack Of Storage Infrastructure & Limitations Associated With Supply Chain
10.3 Vaccination Concerns In Low And Middle Income Countries
11 Market Landscape
11.1 Market Overview
11.2 Market Size & Forecast
11.2.1 Vaccine Supply Chain And Procurement During COVID-19
11.3 Five Forces Analysis
11.3.1 Threat Of New Entrants
11.3.2 Bargaining Power Of Suppliers
11.3.3 Bargaining Power Of Buyers
11.3.4 Threat Of Substitutes
11.3.5 Competitive Rivalry
12 Scale of Operations
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Commercial
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.3.3 Commercial: Geography Segmentation
12.4 Clinical
12.4.1 Market Overview
12.4.2 Market Size & Forecast
12.4.3 Clinical: Geography Segmentation
12.5 Preclinical
12.5.1 Market Overview
12.5.2 Market Size & Forecast
12.5.3 Preclinical: Geography Segmentation
13 Vaccine Type
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Sub-Unit Vaccines
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.3.3 Sub-unit Vaccines: Geography Segmentation
13.4 Live-Attenuated Vaccines
13.4.1 Market Overview
13.4.2 Market Size & Forecast
13.4.3 Live-Attenuated Vaccines: Geography Segmentation
13.5 Inactivated Vaccines
13.5.1 Market Overview
13.5.2 Market Size & Forecast
13.5.3 Inactivated Vaccines: Geography Segmentation
13.6 RNA Vaccines
13.6.1 Market Overview
13.6.2 Market Size & Forecast
13.6.3 RNA Vaccines: Geography Segmentation
13.7 Others
13.7.1 Market Overview
13.7.2 Market Size & Forecast
13.7.3 Others: Geography Segmentation
14 Service
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Fill/Finish
14.3.1 Market Overview
14.3.2 Market Size & Forecast
14.3.3 Fill/Finish: Geography Segmentation
14.4 Analytical & QC Studies
14.4.1 Market Overview
14.4.2 Market Size & Forecast
14.4.3 Analytical & QC Studies: Geography Segmentation
14.5 Cell/Virus Banking
14.5.1 Market Overview
14.5.2 Market Size & Forecast
14.5.3 Cell/Virus Banking: Geography Segmentation
14.6 Others
14.6.1 Market Overview
14.6.2 Market Size & Forecast
14.6.3 Others: Geography Segmentation
15 Geography
15.1 Market Snapshot & Growth Engine
15.2 Geographic Overview
16 North America
16.1 Market Overview
16.2 Market Size & Forecast
16.3 North America: Scale Of Operations
16.4 North America: Vaccine Type Segmentation
16.5 North America: Service Segmentation
16.6 Key Countries
16.6.1 US: Market Size & Forecast
16.6.2 Canada: Market Size & Forecast
17 Europe
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Europe: Scale Of Operations Segmentation
17.4 Europe: Vaccine Type Segmentation
17.5 Europe: Service Segmentation
17.6 Key Countries
17.6.1 Germany: Market Size & Forecast
17.6.2 UK: Market Size & Forecast
17.6.3 France: Market Size & Forecast
17.6.4 Italy: Market Size & Forecast
17.6.5 Spain: Market Size & Forecast
18 APAC
18.1 Market Overview
18.2 Market Size & Forecast
18.3 APAC: Scale Of Operations Segmentation
18.4 APAC: Vaccine Type Segmentation
18.5 APAC: Service Segmentation
18.6 Key Countries
18.6.1 China: Market Size & Forecast
18.6.2 India: Market Size & Forecast
18.6.3 Japan: Market Size & Forecast
18.6.4 South Korea: Market Size & Forecast
18.6.5 Australia: Market Size & Forecast
19 Latin America
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Latin America: Scale Of Operations Segmentation
19.4 Latin America: Vaccine Type Segmentation
19.5 Latin America: Service Segmentation
19.6 Key Countries
19.6.1 Brazil: Market Size & Forecast
19.6.2 Mexico: Market Size & Forecast
19.6.3 Argentina: Market Size & Forecast
20 Middle East & Africa
20.1 Market Overview
20.2 Market Size & Forecast
20.3 Middle East & Africa: Scale Of Operations Segmentation
20.4 Middle East & Africa: Vaccine Type Segmentation
20.5 Middle East & Africa: Service Segmentation
20.6 Key Countries
20.6.1 South Africa: Market Size & Forecast
20.6.2 Saudi Arabia: Market Size & Forecast
20.6.3 Turkey: Market Size & Forecast
21 Competitive Landscape
21.1 Competition Overview
21.2 Market Share Analysis
21.2.1 Ajinomoto
21.2.2 Albany Molecular Research
21.2.3 Catalent
21.2.4 Cytovance Biologics
21.2.5 Emergent BioSolutions
21.2.6 FUJIFILM Diosynth Biotechnologies
21.2.7 GSK
21.2.8 IDT Biologika
21.2.9 Lonza
21.2.10 Merck KGaA
21.2.11 Pfizer
21.2.12 Recipharm
21.2.13 Serum Institute of India
21.2.14 Siegfried
22 Key Company Profiles
22.1 AJINOMOTO
22.1.1 Business Overview
22.1.2 Ajinomoto in the Vaccine Contract Manufacturing Market
22.1.3 Service Offerings
22.1.4 Key Strategies
22.1.5 Key Strengths
22.1.6 Key Opportunities
22.2 ALBANY Molecular Research
22.2.1 Business Overview
22.2.2 Albany Molecular Research in the Vaccine Contract Manufacturing Market
22.2.3 Service Offerings
22.2.4 Key Strategies
22.2.5 Key Strengths
22.2.6 Key Opportunities
22.3 Catalent
22.3.1 Business Overview
22.3.2 Catalent in the Vaccine Contract Manufacturing Market
22.3.3 Service Offerings
22.3.4 Key Strategies
22.3.5 Key Strengths
22.3.6 Key Opportunities
22.4 Cytovance Biologics
22.4.1 Business Overview
22.4.2 Cytovance Biologics in the Vaccine Contract Manufacturing Market
22.4.3 Service Offerings
22.4.4 Key Strategies
22.4.5 Key Strengths
22.4.6 Key Opportunities
22.5 Emergent Biosolutions
22.5.1 Business Overview
22.5.2 Emergent BioSolutions in the Vaccine Contract Manufacturing Market
22.5.3 Service Offerings
22.5.4 Key Strategies
22.5.5 Key Strengths
22.5.6 Key Opportunities
22.6 Fujifilm
22.6.1 Business Overview
22.6.2 Fujifilm in the Vaccine Contract Manufacturing Market
22.6.3 Service Offerings
22.6.4 Key Strategies
22.6.5 Key Strengths
22.6.6 Key Opportunities
22.7 GSK
22.7.1 Business Overview
22.7.2 GSK in the Vaccine Contract Manufacturing Market
22.7.3 Service Offerings
22.7.4 Key Strategies
22.7.5 Key Strengths
22.7.6 Key Opportunities
22.8 IDT Biologika
22.8.1 Business Overview
22.8.2 IDT Biologika in the Vaccine Contract Manufacturing Market
22.8.3 Service Offerings
22.8.4 Key Strategies
22.8.5 Key Strengths
22.8.6 Key Opportunities
22.9 LONZA
22.9.1 Business Overview
22.9.2 Lonza in the Vaccine Contract Manufacturing Market
22.9.3 Service Offerings
22.9.4 Key Strategies
22.9.5 Key Strengths
22.9.6 Key Opportunities
22.10 MERCK KGAA
22.10.1 Business Overview
22.10.2 Merck in the Vaccine Contract Manufacturing Market
22.10.3 Service Offerings
22.10.4 Key Strategies
22.10.5 Key Strengths
22.10.6 Key Opportunities
22.11 PFIZER
22.11.1 Business Overview
22.11.2 Pfizer in the Vaccine Contract Manufacturing Market
22.11.3 Service Offerings
22.11.4 Key Strategies
22.11.5 Key Strengths
22.11.6 Key Opportunities
22.12 RECIPHARM
22.12.1 Business Overview
22.12.2 Recipharm in the Vaccine Contract Manufacturing Market
22.12.3 Service Offerings
22.12.4 Key Strategies
22.12.5 Key Strengths
22.12.6 Key Opportunities
22.13 SERUM Institute of India
22.13.1 Business Overview
22.13.2 Serum Institute of India in the Vaccine Contract Manufacturing Market
22.13.3 Service Offerings
22.13.4 Key Strategies
22.13.5 Key Strengths
22.13.6 Key Opportunities
22.14 SIEGFRIED
22.14.1 Business Overview
22.14.2 Siegfried in the Vaccine Contract Manufacturing Market
22.14.3 Service Offerings
22.14.4 Key Strategies
22.14.5 Key Strengths
22.14.6 Key Opportunities
23 Other Prominent Vendors
23.1 Cobra Biologics
23.1.1 Business Overview
23.1.2 Service Offerings
23.2 Baxter Healthcare
23.2.1 Business Overview
23.2.2 Service Offerings
23.3 Goodwin Biotechnology
23.3.1 Business Overview
23.3.2 Service Offerings
23.4 KBI Biopharma
23.4.1 Business Overview
23.4.2 Service Offerings
23.5 Sanofi
23.5.1 Business Overview
23.5.2 Service Offerings
23.6 Biomarc
23.6.1 Business Overview
23.6.2 Service Offerings
23.7 Bavarian Nordic
23.7.1 Business Overview
23.7.2 Service Offerings
23.8 Charles River Laboratories
23.8.1 Business Overview
23.8.2 Service Offerings
23.9 Boehringer Ingelheim
23.9.1 Business Overview
23.9.2 Service Offerings
23.10 Samsung Biologics
23.10.1 Business Overview
23.10.2 Service Offerings
23.11 Meridian Life Science
23.11.1 Business Overview
23.11.2 Service Offerings
23.12 Wacker Biotech B.V
23.12.1 Business Overview
23.12.2 Service Offerings
23.13 Jubilant Hollisterstier
23.13.1 Business Overview
23.13.2 Service Offerings
23.14 Abbvie
23.14.1 Business Overview
23.14.2 Service Offerings
23.15 Novasep
23.15.1 Business Overview
23.15.2 Service Offerings
23.16 Kemwell Biopharma
23.16.1 Business Overview
23.16.2 Service Offerings
23.17 Northway Biotech
23.17.1 Business Overview
23.17.2 Service Offerings
23.18 Midas Pharma
23.18.1 Business Overview
23.18.2 Service Offerings
23.19 ALCAMI
23.19.1 Business Overview
23.19.2 Service Offerings
23.20 Cambrex
23.20.1 Business Overview
23.20.2 Service Offerings
23.21 Asymchem
23.21.1 Business Overview
23.21.2 Service Offerings
23.22 Pharmaceutics International
23.22.1 Business Overview
23.22.2 Service Offerings
23.23 Sharp
23.23.1 Business Overview
23.23.2 Service Offerings
23.24 Singota Solutions
23.24.1 Business Overview
23.24.2 Service Offerings
23.25 Thermo Fisher Scientific
23.25.1 Business Overview
23.25.2 Service Offerings
23.26 Kaneka Eurogentec
23.26.1 Business Overview
23.26.2 Service Offerings
23.27 Richter-Helm Biologics
23.27.1 Business Overview
23.27.2 Service Offerings
23.28 OLOGY Bioservices
23.28.1 Business Overview
23.28.2 Service Offerings
23.29 Corden Pharma
23.29.1 Business Overview
23.29.2 Service Offerings
23.30 Cerbios Pharma
23.30.1 Business Overview
23.30.2 Service Offerings
23.31 BSP Pharmaceuticals
23.31.1 Business Overview
23.31.2 Service Offerings
23.32 Joinn Biologics
23.32.1 Business Overview
23.32.2 Service Offerings
23.33 Eurofins Scientific
23.33.1 Business Overview
23.33.2 Service Offerings
23.34 Probiogen
23.34.1 Business Overview
23.34.2 Service Offerings
23.35 ESCO Aster
23.35.1 Business Overview
23.35.2 Service Offerings
23.36 Genovior Biotech
23.36.1 Business Overview
23.36.2 Service Offerings
23.37 AGC Biologics
23.37.1 Business Overview
23.37.2 Service Offerings
23.38 EIRGENIX
23.38.1 Business Overview
23.38.2 Service Offerings
23.39 Amaran Biotech
23.39.1 Business Overview
23.39.2 Service Offerings
23.40 EDEN Biologics
23.40.1 Business Overview
23.40.2 Service Offerings
23.41 ABZENA
23.41.1 Business Overview
23.41.2 Service Offerings
23.42 ALDEVRON
23.42.1 Business Overview
23.42.2 Service Offerings
23.43 Cell Culture Company
23.43.1 Business Overview
23.43.2 Service Offerings
23.44 Taron Solutions
23.44.1 Business Overview
23.44.2 Service Offerings
23.45 MABPLEX
23.45.1 Business Overview
23.45.2 Service Offerings
23.46 AXCELLERATE Pharma
23.46.1 Business Overview
23.46.2 Service Offerings
23.47 WUXI Biologics
23.47.1 Business Overview
23.47.2 Service Offerings
23.48 Therapure Biopharma
23.48.1 Business Overview
23.48.2 Service Offerings
24 Report Summary
24.1 Key Takeaways
24.2 Strategic Recommendations
25 Quantitative Summary
25.1 Market By Scale Of Operation
25.1.1 North America: Scale of Operations Segmentation
25.1.2 Europe: Scale of Operations Segmentation
25.1.3 APAC: Scale of Operations Segmentation
25.1.4 Latin America: Scale of Operations Segmentation
25.1.5 Middle East & Africa: Scale of Operations Segmentation
25.2 Market By Vaccine Type
25.2.1 North America: Vaccine Type Segmentation
25.2.2 Europe: Vaccine Type Segmentation
25.2.3 APAC: Vaccine Type Segmentation
25.2.4 Latin America: Vaccine Type Segmentation
25.2.5 Middle East & Africa: Vaccine Type Segmentation
25.3 Market By Service
25.3.1 North America: Service Segmentation
25.3.2 Europe: Service Segmentation
25.3.3 APAC: Service Segmentation
25.3.4 Latin America: Service Segmentation
25.3.5 Middle East & Africa: Service Segmentation
25.4 Market By Geography
25.4.1 Commercial: Geography Segmentation
25.4.2 Clinical: Geography Segmentation
25.4.3 Preclinical: Geography Segmentation
25.4.4 Sub-Unit Vaccines: Geography Segmentation
25.4.5 Live-attenuated Vaccines: Geography Segmentation
25.4.6 Inactivated Vaccines: Geography Segmentation
25.4.7 RNA Vaccines: Geography Segmentation
25.4.8 Others: Geography Segmentation
25.4.9 Fill/Finish: Geography Segmentation
25.4.10 Analytical & QC Studies: Geography Segmentation
25.4.11 Cell/Virus Banking: Geography Segmentation
25.4.12 Others: Geography Segmentation
26 Appendix
26.1 Abbreviations
Select a license type that suits your business needs
Single User Licence
- Report accessible by one user only
- Free 10% or 3 days of customization
- Free post-sale service assistance
- Continuous support through email
5 User Licence
- Report accessible by 5 users within the organization
- Free 15% or 4.5 days of customization
- Continuous support through email and telephone
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
- Free Datasheet worth $1500
- Report accessible by the entire organization
- Free 20% or 6 days of customization
- Free post-sale service assistance
- Continuous support through email and telephone
- Direct access to lead analysts
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
- Report accessible by 1 user only
- Free 15% or 32 hours of customization
- Free post-sale service assistance
- Direct access to lead analysts
Frequently Asked Questions
How big is the vaccine contract manufacturing market?
Which segment is likely to generate the largest revenue during the forecast period?
Which region has the largest number of vaccine manufacturers?
Who are the top vaccine manufacturers?
How has COVID-19 pandemic affected contract manufacturing companies?
What limitations are associated with the supply of COVID-19 vaccines for CMOs?
Other RELATED Reports
COVID-19 Diagnostics Market - Global Outlook and Forecast 2021-2026
Published : December 2020
Blood Glucose Monitoring Devices Market - Global Outlook and Forecast 2021-2026
Published : December 2020
Medical Device Contract Manufacturing Market - Global Outlook and Forecast 2021-2026
Published : March 2021